Intravitreal antivascular endothelial growth factor (anti-VEGF) treatment has drastically
improved the visual and anatomical outcomes in patients with diabetic macular edema …

Inflammation is substantially contributing to the development and worsening of diabetic
retinopathy in general and diabetic macular edema (DME) in particular, which provides the …

Purpose To investigate disorganization of retinal inner layers (DRIL) as a biomarker in eyes
with diabetic macular oedema (DME) treated by intravitreal dexamethasone (DEX) implant …

Diabetic retinopathy is a major retinal disorder and a leading cause of blindness. Diabetic
macular edema (DME) is an ocular complication in patients with diabetes, and it can impair …

Diabetic macular edema (DME) represents a prevalent and disabling eye condition. Despite
that DME represents a sight‐threatening condition, it is also among the most accessible to …

Placental growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF)
family. Upon binding to VEGF-and neuropilin-receptor sub-types, PlGF modulates a range of …

Center-involving diabetic macular edema (DME) is a leading cause of vision impairment in
working-age adults. While its management is particularly challenging in a poorly compliant …

Purpose To evaluate the efficacy, effect profile, and safety of dexamethasone implant on
diabetic macular edema (DME) in a real-life setting, further comparing results by DME …

Diabetic macular edema (DME) is the most common cause of vision loss in diabetic eyes,
and due to the rapid rise in the number of diabetic patients, the treatment burden has …

Aims To provide 2-year follow-up data on eyes with diabetic macular edema (DME) that
were non-responsive after three initial anti-vascular endothelial growth factor (VEGF) …